The Best Non Comedogenic Makeup for a Full Beat, Sans Breakout
When you have acne-prone skin, the best non-comedogenic makeup should be top of mind to avoid further breakouts. I'm militant about my product selection in the pursuit for clearer skin—every cleanser, serum, and SPF formulation is vetted and patch-tested before earning a place in my routine. But it wasn't until a recent facial with celebrity aesthetician Sofie Pavitt that I realized my carefully curated complexion might still be under siege—this time, by my own makeup products.
Celebrity makeup artist Andrea Ventura agrees. 'It's critical to avoid pore-clogging makeup especially if you have sensitive skin, oily skin, or acne-prone skin. For those with any of these skin types, using makeup with comedogenic ingredients ultimately traps bacteria and oil in pores, is clogging your pores, leading to more breakouts,' Ventura tells Vogue.
Vogue's Non-Comedogenic Makeup Picks
In This Story
Rather than cross my fingers whenever I try a new powder blush or foundation, I decided to take control. Call it my beauty bag reckoning—a spring clean guided by acne-safe ingredient lists, and comedogenicity ratings. Inspired by Pavitt's advice of avoiding all comedogenics while on a skin-clearing protocol, I took to scanning every label with the scrutiny of a chemist, purging anything that didn't pass the acne-safe test. 'Why risk it? Minimize the risk of pore-clogging from triggers, and your skin will clear faster,' Pavitt previously told Vogue, and the same concept can be applied to cosmetics.
One word of warning: while many brands claim their products are non-comedogenic, don't take the label at face value. I've made a habit (or perhaps, obsession) of pasting ingredient lists into Sofie Pavitt's pore-clogging checker—and let's just say it's exposed more than a few imposters. The result? A tighter, more intentional edit of color cosmetics. The clean-out focused strictly on complexion products—foundation, concealer, powders—while eyes, lips, and brows got a free pass as the lesser of acne-prone areas.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
33 minutes ago
- Medscape
Merck's Potential Blockbuster Cholesterol Pill Succeeds in Late-stage Studies
(Reuters) -Merck's oral cholesterol pill succeeded in two late-stage studies, marking a win for the drugmaker as it focuses on the development of growth drivers beyond its cancer drugs and vaccines. The company is searching for its next blockbuster candidate as its major revenue driver, Keytruda, is expected to lose patent protection by the end of the decade. Merck's non-statin cholesterol drug, enlicitide decanoate, is being tested for the treatment of hyperlipidemia, a condition that causes elevated buildup of fat in the blood vessels and can lead to heart attacks and strokes. Enlicitide works by blocking PCSK9, a protein that plays a crucial role in regulating cholesterol levels, while statins block an enzyme the liver uses to make cholesterol. BMO Capital Markets analyst Evan Seigerman said Merck's drug could potentially provide a "multi-billion dollar opportunity" that expands the PCSK9 market beyond current injectable therapies. The drug showed meaningful reductions in LDL-C cholesterol, commonly referred to as "bad cholesterol", when compared to placebo and other oral non-statin therapies, Merck said. However, Leerink analysts have noted that Astrazeneca's AZD0780 is a "credible threat" as it has shown a 50.7% reduction in LDL-C levels during a trial. Merck has not given the details on LDL-C reduction for enlicitide. The drug was tested in patients who have a history of, or are at risk for a type of heart disease, and were treated with a statin. Shares of Merck were up 2% in premarket trading. Verve Therapeutics is also developing a gene therapy to reduce high cholesterol levels, which is expected to be used in combination with other drugs. (Reporting by Christy Santhosh in Bengaluru; Editing by Shinjini Ganguli)
New York Times
an hour ago
- New York Times
Trump Budget's Caps on Grad School Loans Could Worsen Doctor Shortage
President Trump's proposed budget would make deep cuts in government health plans and medical research, and, critics say, could also make finding a doctor more difficult: It restricts loans that students rely on to pursue professional graduate degrees, making the path to becoming a physician harder even as doctor shortages loom and the American population is graying. The domestic policy bill, which passed in the House last month, would cap direct federal unsubsidized loans at $150,000 — far less than the cost of obtaining a medical education — and phase out the Grad PLUS loans that help many students make up the difference. Medicine, dentistry and osteopathic medicine are among the most expensive graduate programs. Four years of medical education costs $286,454 at a public school, on average, and $390,848 at a private one, according to the Association of American Medical Colleges. Medical school graduates leave with an average debt of $212,341, the association found. The price of a four-year program in osteopathic medicine is $297,881 at a public school, on average, and $371,403 at a private school, according to the American Association of Colleges of Osteopathic Medicine. The average indebtedness of their graduates is $259,196. The proposed loan caps 'will either push students and families into the private loan market, where they take on more risk and have less consumer protection, or simply push people out of higher education altogether,' said Aissa Canchola Bañez, policy director at the Student Borrower Protection Center, a nonprofit advocacy group. Private student loans are also not eligible for Public Service Loan Forgiveness programs, which many students rely on to manage their debt. Students from low-income families may have difficulty qualifying for private loans. Want all of The Times? Subscribe.
CBS News
an hour ago
- CBS News
Salmonella outbreak tied to recalled eggs makes dozens sick across 7 states in the West and Midwest
A salmonella outbreak linked to a large egg recall has made dozens of people sick in seven states in the West and Midwest, federal health officials said Saturday. The August Egg Company recalled about 1.7 million brown organic and brown cage-free egg varieties distributed to grocery stores between February and May because of the potential for salmonella, according to an announcement posted Friday on the Food and Drug Administration's website. At least 79 people in seven states have gotten a strain of salmonella that was linked to the eggs, and 21 people have been hospitalized, the Centers for Disease Control and Prevention said. The recall affects retailers in Arizona, California, Illinois, Indiana, Nebraska, New Mexico, Nevada, Washington and Wyoming. The recalled eggs were sold under brand names including Clover, First Street, Nulaid, O Organics, Marketside, Raleys, Simple Truth, Sun Harvest, and Sunnyside. Plant code numbers for the recalled eggs are P-6562 or CA5330, according to the CDC's website. This Centers for Disease Control and Prevention map shows the locations of people affected by a Salmonella outbreak linked to eggs. Centers for Disease Control and Prevention "August Egg Company's internal food safety team also is conducting its own stringent review to identify what measures can be established to prevent this situation from recurring," the company said in a statement on the FDA's website. "We are committed to addressing this matter fully and to implementing all necessary corrective actions to ensure this does not happen again." Symptoms of salmonella poisoning include diarrhea, fever, severe vomiting, dehydration and stomach cramps. Most people who get sick recover within a week. Infections can be severe in young children, older adults and people with weakened immune systems, who may require hospitalization. The CDC advises people to throw away recalled eggs or return them to the store where they were purchased. Consumers should also wash and disinfect any surfaces that came in contact with the eggs. This is the latest in a string of salmonella-related outbreaks recently involving food. A tomato recall affecting three southern states was upgraded to a Class I recall, the most severe warning by the Food and Drug Administration. The recall was first announced in May over potential salmonella contamination. Also, nearly four dozen people across 18 states have gotten sick with salmonella food poisoning tied to recalled cucumbers, according to federal health officials. In an update, the CDC said the expanding outbreak led to at least 16 people being hospitalized.
